Skip to content

Study To Compare The Effectiveness of Centesimal Versus Fifty Millesimal Scale In The Management of Polycystic Ovarian Syndrome

A Randomised Comparative Study To Compare The Effectiveness of Centesimal Versus Fifty Millesimal Scale In The Management of Polycystic Ovarian Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051971
Enrollment
60
Registered
2023-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Individualized Homoeopathic Medicine: Following obtaining consent, allocation of patient will be done on appropriate randomized procedure to receive individualized Homoeopathic medicine

Sponsors

Nehru Homoeopathic Medical College and Hospital University of Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of reproductive age group(18-40 years) 2. Patients with oligomenorrhea (intermenstrual period of more than 35 days for 3 consecutive cycles) or amenorrhea for more than 3 months(2 years after menarche) 3. Patients with ultrasound findings of Polycystic ovary(the polycystic ovary had atleast one of the following: either 12 or more follicles measuring 2-9 mm in diameter or increase ovarian volume more than 10 cubic centimeter). Only one ovary fitting this definition or single occurance of one of the above criteria is sufficient to define polycystic ovary 4. Patients will clinical evidence of hirsutism 5. Patients willing to provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Cases complicated with Cushing disease, hyperprolactinaemia, endometriosis and malignancies etc 3. Cases with adrenal hyperplasia and adrenal tumour 4. Ovarian tumour 5. Significant renal impairment 6. Patients who are terminally ill, under immunosuppressive treatment or self reported immunocompromised state 7. Diagnosed case of mental illness/psychiatric/ life threatening illness affecting quality of life/ any organ failure 8. Substance abuse and/or dependence 9. Patients who are unwilling to take part or not giving consent to join the study or unable to read patient information sheet

Design outcomes

Primary

MeasureTime frame
Primary outcome of the treatment will be assessed by considering the symptomatic improvement of the patient and USG finding before and after treatmentTimepoint: Before and after treatment

Secondary

MeasureTime frame
Assessed by Ferriman Gallwey Scale for Hirsutism and Polycystic Ovarian Syndrome QuestionnaireTimepoint: Assess at an interval of one month till completion of study

Countries

India

Contacts

Public ContactEsha Bhatia

Nehru Homoeopathic Medical College and Hospital

drbipin.jethani@gmail.com9810146343

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026